<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977103</url>
  </required_header>
  <id_info>
    <org_study_id>02/14</org_study_id>
    <nct_id>NCT03977103</nct_id>
  </id_info>
  <brief_title>Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT</brief_title>
  <official_title>Antileukemic Activity of Allogeneic Hematopoietic Stem Cell Transplantation With Fractionated Total Body Irradiation or Total Marrow and Lymph Node Irradiation Followed by Adoptive Immunotherapy With Regulatory and Conventional T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptive immunotherapy
      improve cGvHD/disease free survival after allogeneic HSCT in patients affected by high-risk
      acute leukemias or other hematologic malignancy where HSCT is indicated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Improving cGvHD/disease free survival in patients with high-risk acute leukemias or other
      hematologic malignancy where HSCT is indicated with the use of a regulatory T cell based
      protocol. Hyper-fractionated Total Body Irradiation or Total Marrow and Lymphoid Irradiation
      based conditioning will be followed by the infusion of T regulatory and T conventional cell
      adoptive immunotherapy and a purified CD34+ hematopoietic stem cell graft. Incidence of Non
      Relapse Mortality, Relapse, acute Graft versus Host Disease, chronic Graft versus Host
      Disease, as well as probability of cGvHD/disease free survival will be assessed in patient
      subpopulations separated according to HLA-matching with the donor (HLA-matched HSCT and
      HLA-haploidentical HSCT) and type of disease (acute myeloid leukemia, acute lymphoid
      leukemia, lymphoma, multiple myeloma, myeloproliferative disease, and other).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chronic GvHD/relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate if irradiation based myeloablative conditioning followed by Treg/Tcon adoptive immunotherapy improve chronic GvHD/relapse-free survival (GRFS) after allogeneic HSCT in patients affected by acute leukemias or other hematologic malignancies where HSCT is indicated. GRFS will be assessed in subgroups of patients separated according to HLA-matching with the donor and type of disease (acute myeloid lekemia, acute lymphoid leukemia, other)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>full donor-type engraftment</measure>
    <time_frame>30 days</time_frame>
    <description>neutrophil and platelet engraftment measured by neutrophil counts &gt;500/mmc for 3 consecutive days and platelets count &gt;20000/mmc with 7 consecutive without platelet transfusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>cumulative incidence of grades ≥ 2 acute GvHD</measure>
    <time_frame>6 months</time_frame>
    <description>cumulative incidence of grades ≥ 2 acute GvHD according to NIH consesus criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>cumulative incidence of extensive chronic GvHD</measure>
    <time_frame>2 years</time_frame>
    <description>cumulative incidence of extensive chronic GvHD according to revised NIH consesus criteria (Jagasia et al. BBMT 2015)</description>
  </other_outcome>
  <other_outcome>
    <measure>cumulative incidence of non-relapse mortality</measure>
    <time_frame>2 years</time_frame>
    <description>cumulative incidence of non-relapse mortality, defined as death by any cause in the absence of relapse, as competitive risk versus relapse</description>
  </other_outcome>
  <other_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>2 years</time_frame>
    <description>cumulative incidence of relapse, defined as disease recurrence according to marrow morphology, flow cytometry, cytogenetics, fluorescence in situ hybridization and/or polymerase chain reaction, as competitive risk versus non-relapse mortality</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Other Hematologic Malignant Neoplasms</condition>
  <arm_group>
    <arm_group_label>High dose irradiation conditioning + Treg/Tcon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose irradiation conditioning + Treg/Tcon</intervention_name>
    <description>High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation</description>
    <arm_group_label>High dose irradiation conditioning + Treg/Tcon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML and ALL in complete remission and with high-risk of relapse

          -  AML and ALL primarily chemoresistant or relapsed;

          -  Chronic Myeloid Leukemia in accelerated or blastic phase;

          -  Patients affected by

               -  Multiple myeloma,

               -  Non Hodgkin lymphoma,

               -  Hodgkin lymphoma,

               -  Chronic myeloproliferative syndrome,

               -  Chronic Lymphoid Leukemia,

               -  Other Hematological malignancy at high-risk of relapse or detectable disease and
                  where a HSCT is indicated.

          -  Age &lt;75 years

          -  ECOG ≤ 2

          -  Acceptable lung, liver, kidney, and heart function and absence of relevant psichiatric
             diseases

          -  Signature of the informed consent

        Exclusion Criteria:

          -  Age &gt;75 years

          -  ECOG &gt; 2

          -  Not acceptable lung, liver, kidney, and heart function and presence of relevant
             psichiatric diseases

          -  Pregnancy

          -  No signature of the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Velardi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Of Perugia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Pierini, MD, PhD</last_name>
    <phone>+390755784147</phone>
    <email>antonio.pierini@unipg.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mara Merluzzi, MBioTech</last_name>
    <phone>+393482200239</phone>
    <email>maramerluzzi@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Perugia</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pierini, MD, PhD</last_name>
      <phone>+390755784147</phone>
      <email>antonio.pierini@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>Mara Merluzzi, MBioTech</last_name>
      <phone>+393482200239</phone>
      <email>maramerluzzi@libero.it</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Aristei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurizio Caniglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Carotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franca Falzetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Pierini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loredana Ruggeri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adelmo Terenzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simonetta Saldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilaria Capolsini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Mastrodicasa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Speranza Massei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011 Apr 7;117(14):3921-8. doi: 10.1182/blood-2010-10-311894. Epub 2011 Feb 3.</citation>
    <PMID>21292771</PMID>
  </reference>
  <reference>
    <citation>Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Tognellini R, Reisner Y, Aversa F, Falini B, Velardi A. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014 Jul 24;124(4):638-44. doi: 10.1182/blood-2014-03-564401. Epub 2014 Jun 12.</citation>
    <PMID>24923299</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Andrea Velardi</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

